Could a shot every 6 months end HIV? new study tests lenacapavir in south africa
NCT ID NCT07390409
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will offer young people aged 15-35 in Cape Town a choice of HIV prevention methods: a new twice-yearly injection (lenacapavir), a two-monthly injection (cabotegravir), or daily pills. Researchers want to see which option people stick with over 18 months and how best to deliver these choices in clinics and mobile trucks. The goal is to make HIV prevention easier and more effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenacapavir injection
What this could lead to
If successful, this could provide a convenient twice-yearly injection that helps prevent HIV in young people, potentially improving adherence and reducing new infections.
What could go wrong
This is an early real-world study, not a large phase 3 trial. Results may not apply to other regions, and participants may still face side effects or injection-site reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DTHF Mobile Clinics
Cape Town, WC, 7925, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••